Currently, there are many biopharmaceuticals (recombinant proteins) that are expressed in E.coli, especially, as inclusion bodies which are subsequently extracted, purified and conditioned for sale to the public.

Among the most recognized are:

-Filgrastim

-Molgramostim

-Human insulin

-Interferon alfa 2b

-Interferon Beta 1b

-Interferon Beta 1a

-Interferon

-Somatropin Reference - https://www.researchgate.net/publication/262608486_Recombinant_protein_expression_in_Escherichia_coli_Advances_and_challenges

Biopharmaceuticals are mostly therapeutic recombinant proteins obtained by biotechnological processes. They are derived from biological sources such as organs and tissues, microorganisms, animal fluids, or genetically modified cells and organisms.Although several different expression systems may be employed including mammalian cell lines, insects, and plants, new technological advancements are continuously being made to improve microorganism production of biopharmaceuticals. This investment is justified by the well-characterized genomes, versatility of plasmid vectors, availability of different host strains, cost-effectiveness as compared with other expression systems.